How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Adult Attention Deficit and Hyperactivity Disorder Market
- By Treatment Type: Stimulant Medications, Non-Stimulant Medications, Behavioral Therapy, Cognitive Behavioral Therapy (CBT), Combination Therapy
- By Drug Class: Methylphenidate-based, Amphetamine-based, Selective Norepinephrine Reuptake Inhibitors (SNRIs), Alpha-2 Adrenergic Agonists
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics
- By Patient Demographics: Mild ADHD, Moderate ADHD, Severe ADHD, Comorbid Conditions (e.g., Anxiety, Depression)
- By End User: Adult Patients, Healthcare Providers, Caregivers
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Stimulant Medications leads By Treatment Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 293 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.177 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.185 →
Full report · locked preview
Everything inside the Adult Attention Deficit and Hyperactivity Disorder Market report
A complete, evidence-based study - 12 chapters and 123 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Treatment Type 5
Drug Class 4
Distribution Channel 4
Patient Demographics 4
End User 3
Companies profiled
Shire Pharmaceuticals (Takeda Pharmaceutical Company)
Novartis AG
Eli Lilly and Company
Johnson & Johnson
Teva Pharmaceutical Industries Ltd.
Sunovion Pharmaceuticals Inc. (a subsidiary of Sumitomo Dainippon Pharma)
Otsuka Pharmaceutical Co. Ltd.
H. Lundbeck A/S
Pfizer Inc.
AbbVie Inc.
Mylan N.V. (now part of Viatris)
Akorn Inc.
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Shire Pharmaceuticals (Takeda Pharmaceutical Company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Eli Lilly and Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Johnson & Johnson
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Teva Pharmaceutical Industries Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Sunovion Pharmaceuticals Inc. (a subsidiary of Sumitomo Dainippon Pharma)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Otsuka Pharmaceutical Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →H. Lundbeck A/S
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Pfizer Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →AbbVie Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Mylan N.V. (now part of Viatris)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Akorn Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Supernus Pharmaceuticals Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Ironshore Pharmaceuticals & Development Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Medice Arzneimittel Pütter GmbH & Co. KG
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$3,054M by 2033 · 7.1% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Stimulant Medications62.0
- Non-Stimulant Medications9.8
- Behavioral Therapy7.5
- Cognitive Behavioral Therapy (CBT)8.7
- Combination Therapy12.0
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$582.2M → $1,086M · 8.1%
Europe$405.8M → $742.2M · 7.8%
Asia Pacific$370.5M → $714.6M · 8.6%
Latin America$229.3M → $352.6M · 5.5%
Middle East and Africa$176.4M → $290.7M · 6.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.052026
7.072027
7.082028
7.092029
7.112030
7.122031
7.132032
7.132033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Shire Pharmaceuticals (Takeda Pharmaceutical Company)23.6
- Novartis AG17.4
- Eli Lilly and Company11.1
- Johnson & Johnson3.9
- Teva Pharmaceutical Industries Ltd.9.5
- Sunovion Pharmaceuticals Inc. (a subsidiary of Sumitomo Dainippon Pharma)6.5
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Treatment Type20.6%
Drug Class25.9%
Distribution Channel26.4%
Patient Demographics19.4%
End User7.7%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.1
- Europe23.3
- Asia Pacific22.4
- Latin America11.1
- Middle East and Africa9.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Shire Pharmaceuticals (Takeda Pharmaceutical Company) | 92 | 88 | 82 | 94 | 84 | 80 | 87 |
| Novartis AG | 68 | 77 | 81 | 92 | 74 | 87 | 80 |
| Eli Lilly and Company | 66 | 83 | 80 | 68 | 69 | 82 | 75 |
| Johnson & Johnson | 61 | 57 | 76 | 59 | 61 | 57 | 62 |
| Teva Pharmaceutical Industries Ltd. | 66 | 70 | 75 | 54 | 63 | 60 | 65 |
| Sunovion Pharmaceuticals Inc. (a subsidiary of Sumitomo Dainippon Pharma) | 46 | 48 | 57 | 70 | 63 | 60 | 57 |
| Otsuka Pharmaceutical Co. Ltd. | 61 | 66 | 45 | 58 | 46 | 40 | 53 |
| H. Lundbeck A/S | 59 | 46 | 42 | 58 | 48 | 38 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Shire Pharmaceuticals (Takeda Pharmaceutical Company)
- Novartis AG
- Eli Lilly and Company
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Shire Pharmaceuticals (Takeda Pharmaceutical Company) | ✓ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Novartis AG | ✓ | ◐ | ✓ | ✓ | ◐ | ✓ |
| Eli Lilly and Company | − | ✓ | ✓ | ✓ | − | ✓ |
| Johnson & Johnson | − | − | ◐ | ◐ | ◐ | − |
| Teva Pharmaceutical Industries Ltd. | ◐ | ✓ | ✓ | ◐ | ◐ | ◐ |
| Sunovion Pharmaceuticals Inc. (a subsidiary of Sumitomo Dainippon Pharma) | − | − | ◐ | ◐ | ◐ | ◐ |
| Otsuka Pharmaceutical Co. Ltd. | ◐ | − | ◐ | ◐ | − | − |
| H. Lundbeck A/S | ◐ | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Shire Pharmaceuticals (Takeda Pharmaceutical Company)87
2Novartis AG80
3Eli Lilly and Company75
4Teva Pharmaceutical Industries Ltd.65
5Johnson & Johnson62
6Sunovion Pharmaceuticals Inc. (a subsidiary of Sumitomo Dainippon Pharma)57
7Otsuka Pharmaceutical Co. Ltd.53
8H. Lundbeck A/S49
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Shire Pharmaceuticals (Takeda Pharmaceutical Company)Novartis AG
Challenger1
Strong scale, closing on the leaders.
Eli Lilly and Company
Contender3
Focused players with pockets of strength.
Johnson & JohnsonTeva Pharmaceutical Industries Ltd.Sunovion Pharmaceuticals Inc. (a subsidiary of Sumitomo Dainippon Pharma)
Niche2
Specialists in a single segment or region.
Otsuka Pharmaceutical Co. Ltd.H. Lundbeck A/S
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Treatment Type in North America, then scale across Adult Attention Deficit and Hyperactivity Disorder Market — a $509M beachhead inside a $9.77B market.
Beachhead (SOM)$509Mobtainable near-term
Serviceable (SAM)$3.63Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Stimulant Medications
Best fit — highest urgency & budget in Treatment Type.
Economic buyer78 fit
Non-Stimulant Medications
Strong fit — clear ROI and a fast path to value.
End user65 fit
Behavioral Therapy
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Treatment Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Drug Class & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Distribution Channel
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel25%
Digital / self-serve20%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Treatment Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Adult Attention Deficit and Hyperactivity Disorder Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified25%
Evaluation15%
Closed-won6%
$17.6KCAC
$105KLTV
6.0:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Adult Attention Deficit and Hyperactivity Disorder Market is a resilient opportunity — $3.55B by 2033, compounding at 5.9%.
TAM · 2025$2.24Btoday
TAM · 2033$3.55Bforecast
CAGR5.9%2027–2033
Cumulative$25.7Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$3.55BTotal addressable market
SAM$1.40BServiceable available market
SOM$284MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.9% CAGR
Demand compounds through 2033, outpacing GDP across Treatment Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Treatment Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$3.55BLarge & growingTAM by 2033 at 5.9% CAGR
$1.40BServiceable nowreachable with today’s model
$284MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.77BBear3.9% CAGR
$3.55BBase5.9% CAGR
$4.55BBull7.8% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Drug Class optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Adult Attention Deficit and Hyperactivity Disorder Market — a $10.3B market by 2033. Plan: grow share from 8.0% to 15.8%.
Market size · 2033$10.3Btotal addressable
Market CAGR8.5%2027–2033
Target share15.8%from 8.0% today
Revenue ambition$1.62Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.0% | 15.8% | On track |
| Revenue | $768M | $1.62B | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Behind |
| Gross margin | 37.5% | 44.5% | On track |
| Customer retention | 90.0% | 95.7% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Treatment Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Drug Class capability
A defensible second engine — invest in Drug Class to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Treatment Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Drug Class
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $215M capacity & capability investment
- Greenlight bolt-on M&A in Drug Class
- Authorise North America expansion plan
- Fund R&D program for Treatment Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossBehind
- Input-cost & supply riskOn track
- Regulatory / policy changeAt risk
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Adult Attention Deficit and Hyperactivity Disorder Market conversation — a $4.73B market you can size, segment and defend in minutes.
Market size · 2033$4.73Btotal opportunity
Growth6.0%CAGR to 2033
Addressable buyers973+accounts in scope
Typical ROI7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Treatment Type
Goal Grow share in Treatment Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7×return on cost, year one
< 3 mopayback period
$55K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Shire Pharmaceuticals (Takeda Pharmaceutical Company)Novartis AGEli Lilly and CompanyJohnson & JohnsonTeva Pharmaceutical Industries Ltd.Sunovion Pharmaceuticals Inc. (a subsidiary of Sumitomo Dainippon Pharma)Otsuka Pharmaceutical Co. Ltd.H. Lundbeck A/S+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Adult Attention Deficit and Hyperactivity Disorder Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Adult Attention Deficit and Hyperactivity Disorder Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Adult Arterial Filter Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportAdult Anoscopes Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportAdult Anesthesia Mask Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportPatient Access Solutions Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportAdult and Pediatric ICU Beds Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportAdult Aerosol Mask Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportAdult Adjustable Post-Operative Knee Brace Market
Market size, share, segmentation and regional forecast.
$813M market · 2025 base year
View reportAdult Acute Care Ventilator Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportOptical Measurement Market
Market size, share, segmentation and regional forecast.
$549M market · 2025 base year
View reportAdsorption Ultrasonic Therapy Apparatus Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportPharma Knowledge Management Software Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportCompanion Animal Health Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.